News

CNN1y
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity under new name, Zepbound - CNN
The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes ...
Fierce Pharma7d
After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
NBC News1y
FDA approves Eli Lilly’s Zepbound, a weight loss drug similar to Ozempic and Wegovy - NBC News
FDA approves weight loss drug from Eli Lilly that helped people lose up to 52 pounds. Some analysts predict the weekly injectable medication could become the best-selling drug of all time.
Fox Business8mon
Eli Lilly's tirzepatide is off the FDA's drug shortage list: Here's what it means - Fox Business
The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some ...
First China Weight Loss Drug Rival to Novo, Lilly Emerges
Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...
USA Today1y
Eli Lilly's donanemab, an Alzheimer's drug, gets FDA endorsement - USA TODAY
During the FDA's Peripheral and Central Nervous System Advisory Committee hearing on Monday, officials at Eli Lilly said clinical trials showed the drug slowed cognitive and functional decline for ...
Novo, Lilly race for supremacy in India's anti-obesity drug market
Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for ...
The Washington Post9mon
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug Zepbound, can now meet present and projected national demand, the FDA said in a statement.
New York Post1y
US FDA approves Eli Lilly Alzheimer's drug that slows progress of the disease - New York Post
The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly’s LLY.N donanemab for patients with early Alzheimer’s, making it the second approved drug for slowing th… ...
Hosted on MSN1y
FDA approves Lilly’s new Alzheimer’s drug after delay
The Food and Drug Administration (FDA) on Tuesday approved Eli Lilly’s Alzheimer’s drug, the company announced, clearing the way for another entry into the market of a new class of drugs that ...
Fox Business2y
FDA rejects Lilly’s alzheimer’s drug candidate, seeks more data
The FDA asked Lilly to provide clinical data from at least 100 study subjects who received a minimum of 12 months of treatment with the drug.
The Washington Post1y
Alzheimer’s drug from Eli Lilly wins backing of FDA committee
Alzheimer’s drug from Eli Lilly wins backing of FDA committee. The company’s experimental drug was shown in a clinical trial to slow cognitive decline by 35 percent in early disease stages.